IQVIA Holdings Inc. Common Stock vs Solstice Advanced Materials Inc. Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $261.7 (market cap $42.91B), while Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.68B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 4.4× Solstice Advanced Materials Inc. Common Stock's market cap, and Solstice Advanced Materials Inc. Common Stock pays a 0.49% dividend while IQVIA Holdings Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 6 Days and Solstice Advanced Materials Inc. Common Stock for 0 Days on average.
| IQV | SOLS | |
|---|---|---|
Market Cap | $42.91B | $9.68B |
Volume | 1,333,456 | 1,519,067 |
Sector | Health | Basic Materials |
52-Week High | $275.02 | $88.60 |
52-Week Low | $156.66 | $41.43 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $57.07B | $11.35B |
Dividend Yield | — | 0.49% |
Signals from Pluang's Aura AI — not financial advice
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →